ArticleArteriosclerosis, thrombosis, and vascular biology2017
Glucose Transporter 3 Potentiates Degranulation and Is Required for Platelet Activation.
Open access · bronzeAbstract read
In one paragraph
Article in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- The Glucose Transporter GLUT3 Controls Regulatory T Cell Function.European journal of immunology · 2026Article
- Systemic metabolic dysfunction drives platelet-mediated inflammation, fibrogenesis, and hepatocarcinogenesis in metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Mitochondrial Calcium Uniporter Regulates ITAM-Dependent Platelet Activation.Circulation research · 2025Article
- Article
- Platelets and diseases: signal transduction and advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- Shared genes and relevant potential molecular linkages between COVID-19 and chronic thromboembolic pulmonary hypertension (CTEPH).Journal of thrombosis and thrombolysis · 2025Article
- Mitofusin-2 Regulates Platelet Mitochondria and Function.Circulation research · 2024Article
- Novel 4th-generation phytase improves broiler growth performance and reduces woody breast severity through modulation of muscle glucose uptake and metabolism.Frontiers in physiology · 2024Article
- Review
- Preeclampsia: Platelet procoagulant membrane dynamics and critical biomarkers.Research and practice in thrombosis and haemostasis · 2023Article
- The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming.Cell metabolism · 2022Article
- Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension.Heliyon · 2022Review
- Identification of molecular mechanism and key biomarkers in membranous nephropathy by bioinformatics analysis.American journal of translational research · 2022Article
- Analysis of glucose metabolism byScientific reports · 2021Article
- It takes a village: lessons from collaborative science.The Journal of clinical investigation · 2021Article
- A Multivariate Metabolomics Method for Estimating Platelet Mitochondrial Oxygen Consumption Rates in Patients with Sepsis.Metabolites · 2020Article
- Glucose Metabolism Is Required for Platelet Hyperactivation in a Murine Model of Type 1 Diabetes.Diabetes · 2019Article
- Nox2 NADPH oxidase is dispensable for platelet activation or arterial thrombosis in mice.Blood advances · 2019Article
- Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents.Haematologica · 2019Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Trevor P FidlerFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Elizabeth A MiddletonFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Jesse W RowleyFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Luc H BoudreauFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Robert A CampbellFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Rhonda SouvenirFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Trevor FunariFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Nicolas TessandierFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Eric BoilardFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
Andrew S WeyrichFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.).
E Dale AbelFrom the Department of Pharmacology and Toxicology (T.P.F.), and Program in Molecular Medicine (T.P.F., E.A.M., J.W.R., R.A.C., A.S.W., E.D.A.), University of Utah, Salt Lake City; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City (T.P.F., R.S., T.F., E.D.A.); and Department of Infectious Diseases and Immunity, Centre de Recherche du Centre Hospitalier Universitaire de Québec and Faculté de Médecine de l'Université Laval, Quebec City, Canada (L.H.B., N.T., E.B.). DRCadmin@uiowa.edu.
University of Iowa · USFraternal Order of Eagles · US
Funding
UCD Mutant Mouse Regional Resource CenterU42OD012210 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2012 to 2026
$29.2MHigh-throughput targeted mutagenesis of mouse stem cell linesU01HG004080 · NHGRI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI DE JONG, PIETER J. · 2006 to 2010
$28.1MProduction of Targeted Null Mutations for 10,000 Genes in C57BL/6 ES CellsU01HG004085 · NHGRI · REGENERON PHARMACEUTICALS, INC. · PI VALENZUELA, DAVID MANUEL · 2006 to 2010
$25.3MTranslational Research Skills Development CoreU54HL112311 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S, ZIMMERMAN, GUY A. · 2012 to 2016
$12.9MRESEARCH TRAINING IN HEMATOLOGYT32DK007115 · NIDDK · UNIVERSITY OF UTAH · PI LEIBOLD, ELIZABETH ANN, PRCHAL, JOSEF T · 1986 to 2020
$8.4MUCD KOMP PROJECT REPOSITORYU42RR024244 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LLOYD, KC KENT · 2007 to 2010
$7.9MPROGRAM IN HEMOSTASIS AND THROMBOSIS FOR ACADEMICT32HL007344 · NHLBI · UNIVERSITY OF IOWA · PI Anil Kumar Chauhan, Steven R Lentz · 1985 to 2026
$6.5MInterdisciplinary Training Program in MetabolismT32DK091317 · NIDDK · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI SCOTT A SUMMERS · 2011 to 2026
$4.8MMultidisciplinary Pulmonary and Critical Care Training ProgramT32HL105321 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Ramsey Hachem, Robert Paine · 2010 to 2026
$4.5MThe Effects of ART on Platelets and HIV-Associated ThrombosisR01HL126547 · NHLBI · UNIVERSITY OF UTAH · PI PLANELLES, VICENTE, RONDINA, MATTHEW THOMAS · 2014 to 2017
$3.0MNovel nAChR-Targeted PeptidesR01GM103801 · NIGMS · UNIVERSITY OF UTAH · PI MCINTOSH, J MICHAEL · 2012 to 2019
$2.4MThe Platelet Metabolome in ObesityK01GM103806 · NIGMS · UNIVERSITY OF UTAH · PI ROWLEY, JESSE · 2012 to 2016
$802kCIHRNCRR NIH HHS U42 RR024244NHGRI NIH HHS U01 HG004080NHGRI NIH HHS U01 HG004085NHLBI NIH HHS F32 HL128008NHLBI NIH HHS R01 HL126547NHLBI NIH HHS T32 HL007344NHLBI NIH HHS T32 HL105321NHLBI NIH HHS U54 HL112311NIDDK NIH HHS T32 DK007115NIDDK NIH HHS T32 DK091317NIGMS NIH HHS K01 GM103806NIGMS NIH HHS R01 GM103801NIH HHS U42 OD012210
Abstract
objectiveOn activation, platelets increase glucose uptake, glycolysis, and glucose oxidation and consume stored glycogen. This correlation between glucose metabolism and platelet function is not well understood and even less is known about the role of glucose metabolism on platelet function in vivo. For glucose to enter a cell, it must be transported through glucose transporters. Here we evaluate the contribution of GLUT3 (glucose transporter 3) to platelet function to better understand glucose metabolism in platelets. APPROACH AND
resultsPlatelet-specific knockout of GLUT3 was generated by crossing mice harboring GLUT3 floxed allele to a PF4 (platelet factor 4)-driven Cre recombinase. In platelets, GLUT3 is localized primarily on α-granule membranes and under basal conditions facilitates glucose uptake into α-granules to be used for glycolysis. After activation, platelets degranulate and GLUT3 translocates to the plasma membrane, which is responsible for activation-mediated increased glucose uptake. In vivo, loss of GLUT3 in platelets increased survival in a collagen/epinephrine model of pulmonary embolism, and in a K/BxN model of autoimmune inflammatory disease, platelet-specific GLUT3 knockout mice display decreased disease progression. Mechanistically, loss of GLUT3 decreased platelet degranulation, spreading, and clot retraction. Decreased α-granule degranulation is due in part to an impaired ability of GLUT3 to potentiate exocytosis.
conclusionsGLUT3-mediated glucose utilization and glycogenolysis in platelets promotes α-granule release, platelet activation, and postactivation functions.
Indexed as
Cell DegranulationPlatelet ActivationAnimalsArthritis, ExperimentalBlood GlucoseBlood PlateletsCytoplasmic GranulesExocytosisGenotypeGlucose Transporter Type 3GlycogenolysisGlycolysisHumansMaleMice, Inbred C57BLMice, KnockoutBlood GlucoseGlucose Transporter Type 3SLC2A3 protein, humanSlc2a3 protein, mouseglucoseinflammationmetabolismplateletsthrombosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.